Director/PDMR Shareholding

RNS Number : 0590H

Mediclinic International plc

02 June 2017

 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

2 June 2017

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

Awards under the Company's Short-Term Incentive Scheme

On 1 June 2017, awards over ordinary shares in Mediclinic (the "Shares") were granted to the following Directors and other persons discharging managerial responsibilities ("PDMRs") under the rules of the Company's Short-Term Incentive ("STI") Scheme, which was approved by shareholders in December 2015:

Name	Director/ PDMR	Number of Shares awarded under the Short Term Incentive Scheme
Danie Meintjes	Director	27,187
Jurgens Myburgh	Director	10,815

Nil consideration per share was paid for the grant of the awards. The vesting of an award is subject to employment conditions; no further performance conditions apply. 

The following notification made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation relates to the Company's STI Scheme.

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Daniël Petrus Meintjes
2.	Reason for the notification
a)	Position / status	Chief Executive Officer of the Company
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted under the Company's Short Term Incentive Scheme
c)	Price(s) and volume(s)	Price(s) Volume(s) Nil cost 27,187
d)	Aggregated information Aggregated volume Price	27,187 ZAR0.00
e)	Date of the transaction	1 June 2017
f)	Place of the transaction	Johannesburg Stock Exchange

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Petrus Jurgens Myburgh
2.	Reason for the notification
a)	Position / status	Chief Financial Officer of the Company
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted under the Company's Short Term Incentive Scheme
c)	Price(s) and volume(s)	Price(s) Volume(s) Nil cost 10,815
d)	Aggregated information Aggregated volume Price	10,815 ZAR0.00
e)	Date of the transaction	1 June 2017
f)	Place of the transaction	Johannesburg Stock Exchange

About Mediclinic International plc

Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.

Mediclinic comprises 74 hospitals and 37 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 16 private acute care facilities and 4 clinics in Switzerland with more than 1 600 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 31 clinics with more than 700 inpatient beds in the United Arab Emirates.

During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Capita Company Secretarial Services Limited

Victoria Dalby

[phone]

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[e-mail]

[phone]

Media queries

FTI Consulting

Brett Pollard/Debbie Scott (UK)

[phone]

Frank Ford (South Africa)

[phone]

Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom

Website: www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc

JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

 

END

 

 

DSHBSGDLXDGBGRD